Moxonidin Stada (Moxonidine)

Moxonidine acts as a selective agonist at central imidazoline I1 receptors. Activation of these receptors diminishes sympathetic outflow from the brain, leading to reduced peripheral vascular resistance, lower heart rate, and a consequent decrease in arterial blood pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood pressure, response, and tolerability. The prescriber will start with a low dose and may adjust it gradually to achieve optimal blood pressure control while monitoring for side effects.

Safety data for moxonidine during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, offering a different mechanism from ACE inhibitors, ARBs, calcium‑channel blockers, or beta‑blockers. It is particularly useful when a centrally acting agent is desired, and it may have a lower incidence of metabolic side effects compared with some other central antihypertensives.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original blister or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Moxonidin Stada is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and whether the dose should be taken in the morning or evening.

The most serious adverse events include severe hypotension, marked bradycardia, allergic reactions such as rash or angioedema, hepatic dysfunction, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, or signs of an allergic reaction.

Moxonidin Stada should be avoided in patients with severe hepatic impairment, known hypersensitivity to moxonidine, or in those who are already on multiple central sympatholytic agents that could cause excessive blood‑pressure lowering. Clinicians should also exercise caution in patients with bradyarrhythmias or unstable heart conditions.